FH on a Cholesterol Test vs FH on a DNA Test

If you have been diagnosed with familial hypercholesterolaemia and you are now filling in a life insurance application, one fact settles what an insurer can and cannot see: how the diagnosis was reached. A cholesterol test is not a genetic test. A DNA test is. Those are two routes to the same diagnosis, and UK life insurance rules treat them in opposite ways.

A lipid profile — the blood test that measures your cholesterol — is ordinary medical evidence. It is fully disclosable, and an underwriter is entitled to ask about it and to use it. A predictive DNA test that pins down the specific gene fault behind familial hypercholesterolaemia is a genetic test result, and under the UK Code on Genetic Testing and Insurance an insurer cannot ask you for it or use it for life cover. Same condition; two different disclosure positions.

The reassuring part is that this matters less than it first looks. Because your cholesterol has been measured either way, the clinical picture an underwriter can see is much the same whether or not you ever had the DNA test. The genetic result adds a protected layer. It does not hide the numbers underneath it.

The short answer: the blood test is disclosable, the DNA test is not

Familial hypercholesterolaemia, usually shortened to FH, is diagnosed in two overlapping ways. The clinical route reads your cholesterol figures alongside your family history and, often, physical signs. The genetic route sequences the genes that cause it and reports whether a fault is present. Many people have had both, in that order.

For an insurer, only the second route produces something protected. A cholesterol reading is the result of a routine blood test, and a routine blood test sits entirely outside the genetic testing rules. So a very high LDL cholesterol result, the FH diagnosis your lipid clinic wrote down, and the statin you were started on are all ordinary medical facts that a life application may ask about and that you must answer with care.

The DNA result is the part that is walled off. A predictive genetic test — one that examines your DNA to say whether an inherited condition is present — cannot be requested by a life insurer, and you are not expected to volunteer an unfavourable one. That protection applies to the fault behind FH exactly as it applies to any other predictive result.

What familial hypercholesterolaemia actually is

FH is an inherited condition that leaves the body unable to clear LDL cholesterol from the blood properly, so the level runs high from birth rather than creeping up with age and diet. Left untreated, that lifelong exposure raises the risk of early coronary heart disease. Treated — usually with a statin, sometimes with additional medication — the outlook is very different, which is the whole point of finding it early.

It is more common than most people assume. The NHS estimates that familial hypercholesterolaemia affects in the region of one in every 250 people in the UK, and the large majority have never been diagnosed.

Source: NHS, Familial hypercholesterolaemia, nhs.uk.

Part of the reason so many cases go unfound is that FH is usually silent for years. There may be no symptom at all until a heart problem announces it, though some people develop visible signs such as fatty deposits around the eyes or in the tendons. It is frequently picked up only after a relative has an early heart attack and a doctor starts asking about the wider family.

Because the raised cholesterol is present for decades, the clinical evidence tends to be extensive by the time anyone applies for cover: years of lipid results, a specialist letter, a prescription. That is the material an underwriter works from, and none of it depends on a DNA test having been done. You can read the NHS overview of familial hypercholesterolaemia for how it is identified and managed.

Why a cholesterol test is not a genetic test

The line the Code draws is about what is being examined. A genetic test looks at your DNA or chromosomes. A lipid profile measures a substance in your blood. The first is protected; the second is not, no matter how strongly the result points towards an inherited cause.

This is the distinction almost nobody makes, and it is the one that resolves the whole question. It means the same diagnosis can be visible or protected depending purely on which test produced the evidence in front of the underwriter.

NICE sets out the clinical criteria that make a doctor suspect FH in the first place, including a total cholesterol above 7.5 mmol per litre in an adult combined with a personal or family history of early coronary heart disease. Those are cholesterol figures, not gene results, which is exactly why they sit on the disclosable side of the line.

Source: National Institute for Health and Care Excellence, clinical guideline CG71, Familial hypercholesterolaemia: identification and management.

The protection for the DNA result comes from the Code on Genetic Testing and Insurance published by the Association of British Insurers, a voluntary agreement between the insurance industry and government. Under it, insurers do not ask for or use predictive genetic results, with a single narrow exception: a Huntington's disease result, and only where the total life cover applied for is above £500,000. FH is not on that list, so the FH gene result is never askable for life insurance at any sum.

Source: HM Government and Association of British Insurers, Code on Genetic Testing and Insurance.

What an underwriter can see either way

Here is the point that takes the fear out of the question. Whether or not you ever had a DNA test, the underwriter is looking at broadly the same evidence, because the thing that drives the underwriting is your cholesterol and how well it is controlled — and that has already been measured and recorded.

A raised cholesterol reading, and a diagnosis of FH resting on it, can lead an insurer to offer cover on adjusted terms rather than standard ones. What matters to that decision is your treated cholesterol level, whether you take your medication, whether there is existing heart disease, and the ordinary risk factors of weight, blood pressure and smoking. A well-controlled level on treatment is a very different application from an untreated one. None of that assessment needs the gene result, and the outcome always depends on the individual insurer's underwriting.

So the DNA test does not expose you to something the cholesterol test would have hidden. If anything the reverse is true: the protected result is the one an insurer cannot touch, while the blood results were always going to be part of the picture. The same logic applies to other blood-based checks that are fully usable — for example, a positive cotinine test on a life application is used precisely because it is a routine blood or saliva test rather than a genetic one.

It is also worth knowing that insurers do not underwrite FH identically. One may accept a well-controlled applicant on standard terms, another may apply a modest loading for the same figures, and a third may weigh existing heart disease more heavily than the cholesterol itself. That spread is the practical case for comparing insurers rather than assuming a diagnosis closes doors, and it is where an FCA-authorised broker earns their place by knowing which insurers view a treated lipid condition most favourably.

Answering the application with reasonable care

UK applications are governed by the duty to take reasonable care not to make a misrepresentation. You answer the questions you are actually asked, honestly and to the best of your knowledge. For someone with FH, that means being straightforward about the things on the disclosable side of the line.

• Do disclose your cholesterol diagnosis, your readings if asked, and any lipid-lowering medication such as a statin. These are the questions a life application routinely puts.
• Do disclose any heart investigations or cardiac history, because those are ordinary medical facts.
• You need not volunteer a predictive DNA result. The insurer cannot ask for it, and the Code does not expect you to offer an unfavourable one.

The family history questions are their own subject, and they are narrower than people expect. What your own doctor can pass on about your relatives is limited, because your GP does not hold your relatives' records — we set out those boundaries in what your GP can actually tell a life insurer. If you are unsure how a lifelong condition with a strong family pattern is weighed, a family history of heart attacks across two generations works through the same territory from the cardiac side.

Should this put you off having the DNA test?

No, and it is worth being clear about why, because insurance worry is a genuine reason people hesitate over genetic testing. A confirmed genetic diagnosis of FH does two useful things. It clarifies your own treatment, and it opens cascade testing, the process by which your first-degree relatives can be tested for the same known fault and treated early if they carry it. That is a real clinical benefit to your children, brothers and sisters.

And on the insurance side, the result cannot be used against you for life cover. The cholesterol figures that drive the underwriting exist either way, because your lipids have already been measured. So the DNA test adds protection and clinical clarity without adding disclosure. The situation is unlike another common inherited condition where the label alone misleads people — with haemochromatosis, whether you are a carrier or actually affected changes everything, and the same care over what the evidence really shows applies to FH.

If you decide to test after cover is already in place, the position is stronger still: a genetic test taken after your policy has started cannot be asked about or used to change what you already hold. When you are weighing up putting cover in place, you can get life insurance quotes and have an FCA-authorised broker assess it against your actual medical picture. For the wider set of questions about inherited risk, our guide to family history, inherited risk and the odds gathers the related answers in one place.

Across the UK: Scotland, Wales and Northern Ireland

The insurance rules here are UK-wide. The Code on Genetic Testing and Insurance and the duty of reasonable care apply the same way in England, Scotland, Wales and Northern Ireland, so the split between a disclosable cholesterol test and a protected DNA result does not change with where you live.

What differs is the NHS machinery around diagnosis and cascade testing. The NICE guideline applies in England and is generally followed in Wales, while NHS Scotland works to its own clinical guidance, and lipid and inherited-disease services are organised differently across the four nations. None of that alters what an insurer can ask for. It only affects how you reach a diagnosis and how your relatives are offered testing once a fault is confirmed.

Frequently asked questions

Is a cholesterol test a genetic test?

No. The Code on Genetic Testing and Insurance covers tests that examine DNA, and it excludes routine blood tests. A lipid profile showing very high LDL cholesterol is ordinary medical evidence and is fully disclosable, even where it is the basis of a familial hypercholesterolaemia diagnosis.

Does it matter how my FH was diagnosed?

It changes what an insurer can see. Where the diagnosis rests on cholesterol levels and the family pattern, the underlying evidence is all disclosable. Where a DNA test was done, that specific result is protected — but the cholesterol readings and the treatment behind it are not, so the practical picture an underwriter works from is much the same.

Should that put me off DNA testing for FH?

No. A confirmed genetic diagnosis clarifies treatment for you and opens cascade testing for your relatives, and the result cannot be asked for on a life application. The clinical information an insurer can see exists either way, because your cholesterol has already been measured.